Precipio (NASDAQ:PRPO) Posts Quarterly Earnings Results

Precipio (NASDAQ:PRPO) issued its quarterly earnings data on Monday. The biotechnology company reported $0.34 EPS for the quarter, FiscalAI reports. Precipio had a negative return on equity of 10.07% and a negative net margin of 5.50%.The business had revenue of $6.70 million for the quarter.

Precipio Stock Performance

Shares of NASDAQ:PRPO traded up $0.75 during midday trading on Tuesday, hitting $24.65. The company’s stock had a trading volume of 6,203 shares, compared to its average volume of 17,489. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.10 and a current ratio of 1.27. The stock’s 50 day simple moving average is $24.88 and its 200 day simple moving average is $22.76. The stock has a market capitalization of $43.14 million, a price-to-earnings ratio of -30.06 and a beta of 1.22. Precipio has a fifty-two week low of $3.90 and a fifty-two week high of $29.53.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PRPO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precipio in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Precipio from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Trading of Precipio

Several hedge funds have recently added to or reduced their stakes in PRPO. Susquehanna International Group LLP acquired a new stake in Precipio in the 3rd quarter valued at approximately $194,000. Renaissance Technologies LLC lifted its holdings in shares of Precipio by 10.7% during the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after buying an additional 1,400 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 789 shares during the period. Evernest Financial Advisors LLC bought a new stake in shares of Precipio in the third quarter valued at approximately $374,000. Finally, Topline Capital Management LLC acquired a new stake in shares of Precipio in the third quarter worth $1,158,000. Institutional investors own 10.45% of the company’s stock.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.